Recent Agreement with DM WDM and Quark Ventures Results in
Successful Equity Transaction, Significant New Opportunities, and
Future Open Market Support for New Client Pressure BioSciences
WROCLAW, Poland August 14, 2015 Dom Maklerski WDM (WDM), Central
and Eastern Europes (CEE) leading small-cap investment bank, and
Quark Ventures (QV), one of CEEs leading venture funds, today
announced that key progress has been made as a result of a
cooperation agreement recently signed between the financial
services companies and their new client, Massachusetts (USA)-based
Pressure BioSciences, Inc. (OTCQB:
PBIO). This progress includes:
- The sale of 1,000,000 shares of PBIO common stock to a European
institutional investor on Tuesday, August 11th. The shares of PBIO
restricted stock were purchased at an approximate 78% premium to
market by an investment company managed by one of the most
recognized and respected portfolio and fund managers in Poland. In
lieu of cash, PBIO received 601,500 shares in the investment
company, which is publicly-traded on the Main Market of the Warsaw
Stock Exchange. The investment company shares were valued at
approximately $460,000 on the day of the transaction. WDM acted as
the lead financial advisor on this private placement
transaction.
Quark Ventures (a WDM affiliated company) and PBIO recently formed
a joint venture in Poland, called Pressure BioSciences Europe Sp.
z.o.o. (PBIO Europe). PBIO Europe intends to submit several
multi-million dollar grant requests to a special, strategic
economic-development investment portfolio of European Union (EU)
grant programs aimed at supporting innovative companies willing to
develop and manufacture such products in Poland, and to
subsequently commercialize them throughout Poland, the rest of the
EU, and beyond. These programs are expected to deploy almost $100
Billion over the next five years. With QVs guidance, PBIO has begun
the process of preparing at least two grant applications for
submission, based on the Companys powerful and unique Pressure
Cycling Technology (PCT) platform.
In support of their business partner, QV has announced their
intention to purchase up to $250,000 of PBIO common stock in the
open market over the next six months.
As a leading micro and small cap investment bank in Poland, we
are constantly looking for innovative, well-run, undervalued,
high-potential micro-cap companies. We have already partnered with
several companies in this category, introducing them to
high-net-worth and institutional investors in Poland and the
broader CEE area, as we help them finance their development and
build long-term value. We are excited to now be working with PBIO,
as we believe they offer great potential for success and high
return-on-investment, said Wojciech Gudaszewski, Vice President of
WDM.
Richard T. Schumacher, Chief Executive Officer of PBIO, stated,
The WDM Team is as impressive as it gets. In a short period of
time, they have guided us through a very successful securities
transaction, introduced us to many financial and media leaders in
Poland, helped us start the EU grant process, and offered to
support PBIO in the US capital markets. We believe this is the
beginning of a long and rewarding relationship.
About Pressure BioSciences
Pressure BioSciences, Inc. (PBI) (OTCQB:
PBIO) develops, markets, and sells proprietary laboratory
instrumentation and associated consumables to the estimated $6
billion life sciences sample preparation market. Our products are
based on the unique properties of both constant (i.e., static) and
alternating (i.e., pressure cycling technology, or PCT) hydrostatic
pressure. PCT is a patented enabling technology platform that uses
alternating cycles of hydrostatic pressure between ambient and
ultra-high levels to safely and reproducibly control bio-molecular
interactions. To date, we have installed over 250 PCT systems in
approximately 160 sites worldwide. There are over 100 publications
citing the advantages of the PCT platform over competitive methods,
many from key opinion leaders. Our primary application development
and sales efforts are in the biomarker discovery and forensics
areas. Customers also use our products in other areas, such as drug
discovery & design, bio-therapeutics characterization, soil
& plant biology, vaccine development, histology, and forensic
applications.
About DM WDM
WDM is Central and Eastern Europe's leading small cap investment
bank. It has been listed on the Warsaw Stock Exchange since 2007.
Over the past 7 years, WDM has taken over 50 companies public on
the Warsaw Stock Exchange. It has raised over $150,000,000 in
private equity, venture capital and public financing for its
clients. WDM provides access to CEE financing for North American
clients.
About Quark Ventures
Quark Ventures is a leading Central and Eastern European venture
fund with offices in Poland and the United States. Quark has a
unique history of helping North American innovators accelerate
growth by combining cost effective equity with European Union
grants. Quarks passion is exponential innovation in life science,
clean energy and new technology. Quark looks for the game changing
and disruptive innovation that can grow rapidly into global
enterprise.
Contacts:
Justyna Gudaszewska
Crescendo Communications Europe Sp. z.o.o.
Tel (Poland): (+48) 71 79 11 551
Tel (US): 561 705 5659
email: us@wdmcapital.com